IL-22BP/IL22 RA2 Antibody [Alexa Fluor™ Plus 647]

• Reactivity: Hu
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor Plus 647

IL-22BP/IL22 RA2 Antibody [Alexa Fluor™ Plus 647] Summary

• Specificity: Detects human IL‑22BP in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross-reactivity with recombinant human IL‑22 R is observed.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for IL-22BP/IL22 RA2 Antibody [Alexa Fluor™ Plus 647]

• class II cytokine receptor
• CRF2-10
• CRF2-S1IL22BP
• CRF2-X
• Cytokine receptor class-II member 10
• Cytokine receptor family 2 member 10
• Cytokine receptor family type 2, soluble 1
• IL-22 RA2
• IL-22 receptor subunit alpha-2
• IL22BP
• IL-22BP
• IL-22BPCRF2X
• IL22RA2
• IL-22RA2
• IL-22R-alpha-2
• interleukin 22 receptor, alpha 2
• interleukin 22-binding protein
• interleukin-22 receptor subunit alpha-2
• Interleukin-22-binding protein
• MGC150509
• MGC150510
• zcytoR16

Background

Interleukin 22 binding protein (IL-22BP), also known as cytokine receptor family (CRF) 2‑10, CRF2-X, and IL-22 RA2, is a secreted glycoprotein belonging to the type II cytokine receptor family. The IL-22BP gene has been localized to chromosome 6 near the gene for IFN-gamma R1. It encodes a precursor protein of 231 amino acid (aa) residues with a 21 aa putative signal peptide and five potential N-linked glycolsylation sites. IL-22BP lacks a transmembrane and cytoplasmic domain and is most closely related to the extracellular domains of IL‑22 R (CRF2-9) and IL-20 R (CRF2-8), sharing 33% and 34% aa sequence identity, respectively. It also shares sequence homology with the extracellular domains of IL-10 R (29%), IL-10 R beta (30%), the IFN receptors (23‑25%) and tissue factor (26%). IL-22BP antagonizes IL-22 activity by specifically binding IL-22 with high affinity and blocking its interaction with the cell surface IL-22 receptor heteromeric complex composed IL‑22 R and IL‑20 R. IL‑22BP is expressed in multiple tissues. The highest levels of expression are found in breast, lungs and colon.

1. Dumoutier, L. et al. (2001) J. Immunol. 166:7090.
2. Xu, W. et al. (2001) Proc. Natl. Acad. Sci. USA 98:9511.
3. Kotenko, S. et al. (2001) J. Immunol. 166:7096.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.